The decision to prescribe a compounded or brand-name glucagon-like peptide 1 (GLP-1) medication for obesity treatment was never simple, but recent developments have complicated it further.

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers told us how they cope. He acknowledged none of these options solves “the ...

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved ... To help alleviate shortages of brand-name GLP-1s, the FDA temporarily authorized compounding ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity medications. But it's not clear if the proposed change will go into effect.

Now, though, on platforms like Instagram and Facebook, ads for oral knock-off versions of GLP-1 drugs are proliferating. After the brand-name GLP-1 drugs went into shortage in 2022, a booming ...

CHRISTMAS is famously a period of indulgences and there’s nothing wrong with partaking in a mince pie or roast with all the ...

For instance, tirzepatide, sold under the brand name Zepbound, binds to both GLP-1 and GIP receptors. While these drugs are effective in inducing weight loss, whether this approach to weight ...

The new class of GLP-1 weight loss drugs have been blockbusters ... Meeting that huge demand has been challenging. The name-brand medications are very expensive and not always covered by insurance.

Semaglutide is sold under the brand name Ozempic when it’s prescribed ... “The staggeringly high discontinuation rates of GLP-1 RA should raise alarms for clinicians, policy makers, and ...

Investigators presented the latest research on the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs ... based on brand names approved by the [Food and Drug Administration] for type ...

Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that ... sold most famously under the brand name Ozempic, for either weight loss, diabetes management or ...